Comment from InOut Labs

Summary: InOut Labs, a national consortium and third-party administrator for DOT drug and alcohol testing, supports the FDA's proposed expansion of 510(k) exemptions for medical devices. The commenter argues that the current FDA clinical pathway is ill-suited for forensic workplace testing and urges the FDA to eventually transfer oversight of these specific technologies to SAMHSA and the NLCP.